INKT•benzinga•
MiNK Therapeutics Announces New Phase 2 Data For Allo-iNKTs At AACR IO Annual Meeting; Study Involves agenT-797 Combined With BOT/BAL For Refractory Gastroesophageal Cancer
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 24, 2025 by benzinga